Cohance Lifesciences Limited share price
NSE: COHANCE · ISIN INE03QK01018
Key numbers
- Market cap
- ₹ 17,571 Cr
- Current price
- ₹ 459.25
- 52-week high / low
- ₹ 918 / 267
- Stock P/E
- 165.8
- Book value
- ₹ 102.0
- Dividend yield
- 0.00%
- ROCE
- 5.7%
- ROE
- 4.7%
- Debt to equity
- 0.10
- Sales growth (3 yrs)
- 18.3%
- Profit growth (3 yrs)
- -24.2%
- 1-year return
- -48.9%
About Cohance Lifesciences Limited
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms (FDE); packaging and clinical trial support services; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 549 | 556 | 545 | 619 | 422 |
| Operating profit | 112 | 121 | 95 | 99 | 1 |
| Net profit | 49 | 74 | 37 | 20 | -24 |
| EPS (₹) | 1.28 | 1.94 | 0.96 | 0.51 | -0.63 |
Concall summary (2026-08-11)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Q1FY27 Pharma CDMO revenue declined by 38.7% year-on-year.
- For one commercial molecule that faced destocking last year, we have now received the restocking order, providing meaningful delivery visibility for Q4 FY27 and FY28.
Growth & demand
- As a result, Sapala reported 2.5x revenue growth in Q1.
- Sapala added revenue of INR274 million, a growth of 2.5x year-on-year, while maintaining a strong EBITDA margin.
Margins & costs
- Consolidated gross margin was at 71.5% compared with 73% in Q1 FY26.
- Adjusted EBITDA was at INR92 million, representing a margin of 2.2%.
Capex & expansion
- In parallel, we are evaluating targeted capacity additions across small molecules, ADCs, API+, and specialty chemicals to support next phase of growth.
- We completed debottlenecking initiatives for a few products, commissioned a new effluent treatment facility at Ankleshwar, and successfully completed 11 customer audits across our API manufacturing sites.
Balance sheet & cash
- The reduction reflects the lower revenue base, negative operating leverage, and the impact of subsidiary consolidation.
- Our balance sheet remains resilient with consolidated net cash of approximately INR2,512 million as of 30th June 2026.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.